Focal segmental glomerulosclerosis (FSGS) market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to boost the market include the increasing prevalence of FSGS, rising focus towards rare diseases, and increasing R&D activity. Moreover, in both developed and emerging markets, increasing demand for the kidney transplants and a higher rate of hospitalizations have been witnessed, due to kidney malfunction. This increases the demand for diagnosis of the initial stage of FSGS diseases during the treatment of kidney diseases. Thus, the burden of glomerulus-related disorders drives the global FSGS market during the forecast period. FSGS is the progressive scarring of the kidney, which is characterized by proteinuria. It is among the rare diseases, which affects kidney function by attacking and damaging the glomeruli. This disease is characterized by kidney defects by birth, obesity, obstructive sleep apnea, sickle cell anemia, viruses, such as HIV, among others.
Primary FSGS has become one of the most common causes of idiopathic glomerular disease in adults. The primary FSGS is usually idiopathic, which refers to the rise of disease without any known, definite or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults. The current therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Steroid therapy is among the most basic and standard treatment with oral prednisone. Some of the emerging companies having their potential drug candidates in the pipeline which include Chemocentryx, Reata, Pharmaceuticals, Retrophin Inc., and Vertex Pharmaceuticals. Since it is a rare disease, specialty clinical-stage companies are likely to get more funds that can leverage the strategic partnership opportunities. Moreover, the companies are directing their R&D efforts toward more targeted therapies as a solution to traditional drug and surgical treatments, which in turn, is expected to fuel the growth of the global focal segmental glomerulosclerosis market.
To Request a Sample of our Report on Focal Segmental Glomerulosclerosis Market: https://www.omrglobal.com/request-sample/focal-segmental-glomerulosclerosis-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Disease Type
- By Disease Management
- By Treatment
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Novartis International AG, Variant Pharmaceuticals, Inc., and AbbVie Inc., among others.
Focal Segmental Glomerulosclerosis Market Report by Segment
By Disease Type
- Primary FSGS
- Secondary FSGS
By Disease Management
- Diagnosis
- Kidney Biopsy
- Creatinine Test
- Other Diagnosis
- Treatment
- Drug Therapy
- Dialysis
- Kidney Transplant
A full Report of Focal Segmental Glomerulosclerosis Market is Available @ https://www.omrglobal.com/industry-reports/focal-segmental-glomerulosclerosis-market
Focal Segmental Glomerulosclerosis Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
